Kairos Pharma Ltd.

KAPA | AMEX

Price Alert Chart Builder DCF Calculator

$1.75

+$0.02 (+1.16%)

At close: Sep 21, 2026, 3:59 PM ET

$1.75

$0 (0.00%)

After-hours: Sep 21, 2026, 6:25 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.16%

(1D)

Rating

Updated: Sep 4, 2026

11.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $5.35M

1D Range

1.72 1.80

52W Range

1.51 9.59

Valuation (TTM)

PE -0.90

PB 1.28

EV/EBITDA -0.48

Valuation (NTM)

Forward PE N/A

Forward PEG -0.02

Price Target $9

Cash Flow

FCF Yield -74.2%

SBC Adj. FCF Yield -79.0%

SBC Impact -6.5%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y -16.7% | -20.1%

FCF 3Y | 5Y -64.5% | -59.8%

Returns

ROA -130.3%

ROE -98.8%

ROIC -143.9%

Financial Health

Net Cash

$2.63M

Current Ratio 11.98

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of an...

Sector Healthcare

Industry Biotechnology

Employees 4

IPO Date Sep 15, 2024

Website kairospharma.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+414.29%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞